SEOUL, South Korea -- Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial ...
Karyopharm Therapeutics is under fresh scrutiny as analysts reaffirm a $28 price target while keeping the central fair value ...
Following is a transcript of their remarks: Vinay Prasad, MD: I'm back with Aaron Goodman and Dr. Al-Ola Abdallah and we're talking about selinexor. Aaron, selinexor, good drug or great drug? How ...
Results from the phase 3 SENTRY trial show that selinexor plus ruxolitinib significantly reduced spleen volume in patients with myelofibrosis.
Karyopharm Therapeutics develops drugs for cancer and other diseases. Its main drug, Xpovio (selinexor), treats multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). Despite gaining ...
The oral selective inhibitor of nuclear export could provide a new therapeutic avenue in daratumumab-naive patients with relapsing refractory multiple myeloma (RRMM). The combination of oral selinexor ...
Karyopharm Therapeutics (KPTI) announced plans to seek a label expansion for its lead asset, selinexor, on Tuesday after the ...
NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced it has submitted a supplemental New Drug ...
Karyopharm Therapeutics (NASDAQ:KPTI) reported top-line results from its phase III SENTRY trial evaluating selinexor in ...
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma This phase II trial ...
NEWTON, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results